August is observed as hair loss awareness month, and we here at Thalocan Research Innovations are proud to join organizations like the National Alopecia Areata Foundation in raising awareness and drawing attention to this significant challenge that can impact a person’s health, confidence and overall well-being. Recently, we partnered with Arash Mostaghimi, MD, MPA, MPH…
Details“The current set up for HS lesion counting in clinical trials and routine practice is far from ideal. Counting multiple lesions in multiple body sites takes time and there is high risk for error. Thalocan’s Lesion Area Mapping Assistant Trial enables sponsors to undertake quality control from the images and site personnel can assess images…
DetailsThalocan Research Innovations has partnered with Arash Mostaghimi, MD, MPA, MPH to develop a comprehensive training for the BETA and BELA to accompany The Severity of Alopecia Tool (SALT), training for a robust and high quality Alopecia assessment curriculum. Our mission is to support clinical raters with a clear understanding of the scoring criteria for…
DetailsThe fourth in our series of Conversations with Portia Combow and living with HS. Thalocan Research Innovations CEO Eric Zudak and Portia discuss the roadblocks she’s encountered with clinical studies. Watch the full webinar/conversation at www.thalocan.com/webinars/.
Thanks to Dr. Amit Garg for his kind words about his experience with Thalocan Research Innovations specifically the development of LAMA – Thalocan’s Lesion Area Mapping assistant. This state-of-the-art tool would not be possible without the invaluable consult and input from Dr. Garg, as well as Professor John Ingram. We’re grateful for their assistance in…
DetailsTRI shares just one of the features of Thalocan’s Lesion Area Mapping Assistant (LAMA) – revolutionizing clinical assessment of HS, among other indications. Learn more at: https://www.thalocan.com/lama/
The fourth in our series of Conversations with Portia Combow and living with HS. Thalocan Research Innovations CEO Eric Zudak and Portia discuss the roadblocks she’s encountered with clinical studies. Watch the full webinar/conversation at www.thalocan.com/webinars/.
Why We Built Thalocan: The Forgotten Links in Dermatology Clinical Trials Interview with Eric Zudak, CEO of Thalocan Research Innovations by Ginger Claremohr, Claremohr Writing Co. There’s a moment in every startup story when frustration turns into fuel. For Eric Zudak, founder of Thalocan Research Innovations, that moment came when a global pharmaceutical company called…
DetailsOld school paper record keeping is time-consuming with a higher potential for missteps. Avoiding this is just ONE of the many reasons we designed LAMA. A patent-pending, BYOD cloud-based solution, Thalocan’s Lesion Area Mapping Assistant (LAMA) is built on a single concept: improve lesion assessment during dermatologic clinical trials with a streamlined, comprehensive and structured…
DetailsTeresa DeHaemer, our Senior Director of Business Strategy shares just a small part of her experience at hashtag#RAD2025 – The Revolutionizing Atopic Dermatitis conference in Nashville, which took place June 6th and 7th. Joined by Tyler White, our Senior Director of Business Development, Thalocan Research Innovations expresses our sincere thanks for all the insight, presentations,…
Details
